Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?

2020

Is liver fibrosis just liver fibrosis? Or do the subtype of collagen, its spatial localization in the liver, its cell of origin, and the time point at which it is synthesized also matter? It is important, since the various collagen subtypes hold different informative values regarding reparative processes in the liver, and as collagens have also emerged as important signaling molecules (1). Novel data have challenged our perception of liver fibrosis and collagens, which may have important implications regarding the development of new biomarkers and anti-fibrotic interventions. The traditional histological analysis of liver biopsies using histochemical collagen stains, such as the Masson's Tr…

Liver Cirrhosis0303 health sciencesPathologymedicine.medical_specialtyHepatologybusiness.industryLiver fibrosismedicine.diseaseFatty Liver03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicineAnimalsHumansCollagenSteatohepatitisbusiness030304 developmental biology
researchProduct

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.

2021

[BACKGROUND & AIMS] Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. [METHODS] We combined new and existing genotype data for 10, 516 cases and 20, 77…

Liver CirrhosisALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC0301 basic medicineCandidate geneALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC; Genome-Wide Association Study; Humans; Liver Cirrhosis BiliaryItalian PBC Study GroupLD SCORE REGRESSIONJapan-PBC-GWAS ConsortiumGenome-wide association studyLocus (genetics)DiseaseSUSCEPTIBILITYPBCChronic liver diseaseBioinformaticsGENETIC ASSOCIATION1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineUK-PBC ConsortiumGenotypeHumansMedicineNetwork-based in silico drug efficacy screeningGenetic associationScience & TechnologyGastroenterology & HepatologyHepatologyLiver Cirrhosis Biliarybusiness.industryBiliaryChinese PBC Consortium1103 Clinical SciencesALSPACmedicine.diseasePBC Consortia030104 developmental biologyMeta-analysisERN RARE LIVER030211 gastroenterology & hepatologyGenomic co-localizationUK-PBCUS PBC ConsortiumERN RARE-LIVERCanadian PBC ConsortiumbusinessLife Sciences & BiomedicineGenome-Wide Association StudyHuman
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

TGF-β2 silencing to target biliary-derived liver diseases

2020

ObjectiveTGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases.DesignAs we also found upregulated TGFB2 in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), we now fathomed the positive prospects of targeting TGF-β2 in early stage biliary liver disease using the MDR2-KO mice. Specifically, the influence of TgfB2 silencing on the fibrotic and inflammatory niche was analysed on m…

Liver CirrhosisATP Binding Cassette Transporter Subfamily B2312Cholangitis SclerosingPrimary sclerosing cholangitisMiceTransforming Growth Factor beta2Liver diseasePrimary biliary cirrhosisCholestasisFibrosisDrug DiscoveryTGF beta signaling pathwayHepatic Stellate CellsAnimalsHumansMedicineGene silencingGene Silencing1506TGF-betaddc:610Mice KnockoutHepatologybiologyLiver Cirrhosis Biliarybusiness.industryfibrosisGastroenterologyprimary sclerosing cholangitisTransforming growth factor betaOligonucleotides Antisensemedicine.diseaseUp-Regulationprimary biliary cirrhosisDisease Models AnimalGene Expression RegulationCancer researchbiology.proteincholestasisbusinessGut
researchProduct

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

2011

INTRODUCTION: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. PATIENTS AND METHODS: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. RESULTS: …

Liver CirrhosisAdultMaleBiopsyHyperlipidemiasFatty Liver/blood/diagnosis/etiology/pathologyRisk AssessmentSeverity of Illness IndexHepatitisBody Mass IndexDiabetes ComplicationsYoung AdultNon-alcoholic Fatty Liver DiseasePredictive Value of TestsRisk FactorsNAFLDLondonMetabolic Syndrome X/blood/*complicationsHumansAspartate AminotransferasesObesityBiological Markers/bloodliver fibrosisAgedMetabolic SyndromeInflammationFerritinChi-Square DistributionPatient SelectionNASHHepatitis/blood/complications/*diagnosisMiddle AgedFibrosisFatty LiverLiver Cirrhosis/blood/*diagnosis/etiologyNomogramsLogistic ModelsHyperlipidemias/blood/complicationsHypertension/blood/complicationsFerritinsHypertensionFerritin; Fibrosis; Inflammation; NAFLD; NASHAspartate Aminotransferases/bloodFemaleDiabetes Complications/blood/diagnosis/etiologyObesity/complicationsBiomarkersFerritins/*blood
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Liver CirrhosisAdultMaleChronic HBsAg carriers; Cirrhosis; Hepatocellular carcinoma; Sex differences; Adult; Aged; Carcinoma Hepatocellular; Female; Hepatitis B Surface Antigens; Hepatitis B Chronic; Humans; Italy; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Sex Factors; Virology; Infectious DiseasesCarcinoma HepatocellularHepatocellular carcinomaLiver CirrhosiHepatitis B Surface AntigenChronic HBsAg carriersHepatitis B ChronicSex FactorsVirologySex differencesHumansChronicAgedChronic HBsAg carrierHepatitis B Surface AntigensCirrhosiCarcinomaLiver NeoplasmsHepatocellularMiddle AgedHepatitis BSex differenceInfectious DiseasesCirrhosisItalyLiverLiver NeoplasmFemaleHuman
researchProduct

Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to …

2018

The purpose of this study was to compare the performance of gadobenate dimeglumine–enhanced MRI and gadoxetic acid–enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction. In this retrospective cross-sectional study, we analyzed the unenhanced phase and the HBP of 131 gadobenate dimeglumine–enhanced MRI examinations (gadobenate dimeglumine group) and 127 gadoxetic acid–enhanced MRI examinations (gadoxetic acid group) performed in 249 cirrhotic patients (181 men and 68 women; mean age, 64.8 years) from August 2011 to April 2017. For each MRI, the contrast enhancement index of the liver parenchyma was calculated and correlated to the Mod…

Liver CirrhosisAdultMaleGadolinium DTPAGadoxetic acidmedicine.medical_specialtyLiver CirrhosiContrast MediaSensitivity and SpecificitySeverity of Illness Index030218 nuclear medicine & medical imagingGadobenic acid03 medical and health sciencesLiver diseaseYoung Adult0302 clinical medicineModel for End-Stage Liver DiseaseMeglumineGadobenic acidRetrospective StudiemedicineGadolinium ethoxybenzyl DTPAOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingRetrospective StudiesNeuroradiologyAgedAged 80 and overCross-Sectional Studiemedicine.diagnostic_testMegluminebusiness.industryMagnetic resonance imagingGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseMagnetic Resonance ImagingCross-Sectional Studies030220 oncology & carcinogenesisFemaleRadiologyNuclear medicinebusinessmedicine.drugHuman
researchProduct

HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey

2007

We assessed the prevalence of gallbladder disease (i.e. gallstones plus cholecystectomy) among patients with liver disease and its association with the severity and aetiology of hepatic injury. Subjects, referred to 79 Italian hospitals, were enrolled in a 6-month period. The independent effect of the severity and aetiology of liver disease on gallstone disease prevalence was assessed by multiple logistic regression analysis. Overall, 4867 subjects tested anti-hepatitis C virus (HCV) positive alone, 839 were hepatitis B virus surface antigen (HBsAg) alone, and 652 had an excessive alcohol intake. The prevalence of gallstone disease was 23.3% in anti-HCV-positive patients, 12.4% in HBsAg pos…

Liver CirrhosisAdultMaleHBsAgmedicine.medical_specialtyCirrhosisAlcohol DrinkingLiver CirrhosiGallbladder diseasePrevalenceInfectious DiseaseGallstonesGastroenterologyLiver diseaseRisk FactorsVirologyInternal medicineHBVPrevalencemedicineHumansCholecystectomyRisk factorAgedCirrhosiHepatologybusiness.industryRisk FactorGallstonesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseInfectious DiseasesItalyGallstoneHCVChronic hepatitiFemalebusinessGallbladder diseaseHumanJournal of Viral Hepatitis
researchProduct

The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients

2015

BACKGROUND/AIMS: Low 25-hydroxyvitamin D serum levels have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC), and experimental evidence suggested a hepatoprotective role of vitamin D via interaction with hepatic vitamin D receptor (VDR). We assessed the hepatic expression of VDR protein and its association with liver disease severity. METHODS: Ninety-one consecutive patients with biopsy-proven G1CHC and available frozen liver tissue were evaluated. Ten subjects without chronic liver diseases and nine patients with autoimmune hepatitis served as controls. The hepatic expression of VDR protein was assessed by Western blot for quantification…

Liver CirrhosisAdultMaleLiver damagemedicine.medical_specialtyLiver CirrhosiEndocrinology Diabetes and MetabolismClinical BiochemistryVDR liver fibrosisLiver damage; VDR liver fibrosisAutoimmune hepatitisBiologySeverity of Illness IndexBiochemistryCalcitriol receptorLiver diseaseEndocrinologyWestern blotFibrosisInternal medicinemedicineVitamin D and neurologyHumansSettore MED/12 - Gastroenterologiamedicine.diagnostic_testBiochemistry (medical)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseEndocrinologyLiverVitamin D3 ReceptorReceptors CalcitriolFemaleHumanThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the e…

2008

We evaluated 1336 hepatitis B surface antigen-positive subjects consecutively observed in 79 Italian hospitals over a 6-month period. The proportion of hepatitis B e antigen-negative cases was 86.4%, that of patients coinfected with hepatitis D virus was 9.7%, and the rate of patients coinfected with hepatitis C virus was 16.8%. Multiple logistic regression analysis showed that age >49 years, alcohol abuse, and anti-hepatitis D virus and anti-hepatitis C virus positivity were independent predictors of progression to liver cirrhosis. © 2007 by the Infectious Diseases Society of America. All rights reserved.

Liver CirrhosisAdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisAdolescentHepatitis D ChronicHepatitis C virusHepacivirusLiver CirrhosiHepacivirusmedicine.disease_causeGastroenterologyVirusFlaviviridaeHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansHepatitis B e AntigensAgedAged 80 and overCross-Sectional StudieHepacivirubiologybusiness.industrySeroepidemiologic StudieHepatitis Delta ViruHepatitis BMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis DVirologyAlcoholismCross-Sectional StudiesInfectious DiseasesItalyDisease ProgressionFemaleHepatitis B e AntigenHepatitis D virusHepatitis Delta VirusbusinessHuman
researchProduct